The Clinical Efficacy of a Sequential Comprehensive Treatment Plan Mainly Based on Surgical Resection for Locally Advanced Oral Cancer

HAN Xiaoqin; ZHOU Junnian; LI Xiaojun; LI Dongshan; WANG Jian

doi:10.3969/j.issn.1672-7185.2023.12.016

Abstract：Objective To explore the clinical efficacy of a sequential comprehensive treatment plan mainly based on surgical resection for locally advanced oral cancer.Methods A total of 89 patients with locally advanced oral cancer admitted to Wuwei Cancer Hospital in Gansu Province from January 2017 to December 2021 were collected,and divided into a surgical group of 61 cases and a non-surgical group of 28 cases.The surgical group received neoadjuvant chemotherapy before surgery,skin flap repair during surgery,and radiation therapy after surgery.The non-surgical group received synchronous chemotherapy combined with radiotherapy.The effects of surgery,neoadjuvant chemotherapy,and skin flap repair on prognosis were compared.Results After treatment,carcinoembryonic antigen,neuron specific enolase and carbohydrate antigen-199 in the operation group were significantly lower than those in the non operation group(P<0.05).The survival time of the surgical group was significantly longer than that of the non-surgical group(median 25.3 months vs.median 19.4 months)(P<0.05).The disease control rate(60.6%vs.53.57%)and survival time(median 27.6 months vs.median 24.0 months)between the TPF subgroup and DBF subgroup in the neoadjuvant chemotherapy regimen were not significant(P>0.05).The survival time of the repair subgroup(median 28.6 months vs.median 25.0 months)was significantly longer than that of the non repair subgroup(P<0.05).Conclusion Compared with non-surgical treatment,the sequential comprehensive treatment plan mainly based on surgical resection can prolong the survival time of locally advanced oral cancer patients,and skin flap repair can further improve the surgical resection effect.However,there is no significant difference in the improvement of preoperative tumor control and survival among different neoadjuvant chemotherapy regimens.